Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial.
Christophe Tournigand
Honoraria - Roche
Benoit Samson
No relevant relationships to disclose
Werner Scheithauer
Consultant or Advisory Role - Roche
Honoraria - Roche
Expert Testimony - Roche
Gérard Lledo
No relevant relationships to disclose
Frédéric Viret
No relevant relationships to disclose
Thierry Andre
Consultant or Advisory Role - Roche
Honoraria - Baxter International; Roche; Sanofi
Jean François Ramée
No relevant relationships to disclose
Nicole Tubiana-Mathieu
No relevant relationships to disclose
Jérôme Dauba
No relevant relationships to disclose
Olivier Dupuis
No relevant relationships to disclose
Yves Rinaldi
No relevant relationships to disclose
May Mabro
No relevant relationships to disclose
Nathalie Aucoin
No relevant relationships to disclose
Ahmed Khalil
No relevant relationships to disclose
Jean Latreille
No relevant relationships to disclose
Christophe Louvet
No relevant relationships to disclose
David Brusquant
No relevant relationships to disclose
Franck Bonnetain
No relevant relationships to disclose
Benoist Chibaudel
No relevant relationships to disclose
Aimery De Gramont
No relevant relationships to disclose